About gt biopharma - GTBP
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.
GTBP At a Glance
GT Biopharma, Inc.
505 Montgomery Street
San Francisco, California 94111
| Phone | 1-415-919-4040 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -28,354,000.00 | |
| Sector | Health Technology | Employees | 1 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GTBP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.465 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.207 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
GTBP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -28,354,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GTBP Liquidity
| Current Ratio | 3.222 |
| Quick Ratio | 3.222 |
| Cash Ratio | 2.978 |
GTBP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -459.621 |
| Return on Equity | -1,377.411 |
| Return on Total Capital | -489.96 |
| Return on Invested Capital | -1,377.411 |
GTBP Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |